Haemonetics Corp. 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended December 28, 2002 (Fiscal Year 2003)
Business Overview: A leader in automated systems and single-use disposables for the collection, processing, and surgical salvage of blood, as well as associated consumables and data management technology.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 28, 2002 |
3 Months Ended Dec 29, 2001 |
9 Months Ended Dec 28, 2002 |
9 Months Ended Dec 29, 2001 |
|---|---|---|---|---|
| Net Revenues | $87,115 | $84,411 | $256,075 | $240,916 |
| Gross Profit | $40,941 | $41,235 | $118,478 | $117,347 |
| Gross Margin | 47.0% | 48.9% | 46.3% | 48.7% |
| Operating Income | $11,822 | $2,806 | $31,340 | $25,292 |
| Net Income | $10,347 | $2,432 | $23,902 | $22,324 |
| Diluted EPS | $0.42 | $0.09 | $0.95 | $0.82 |
| Cash from Operations (9mo) | $29,325 | $16,195 | ||
| Working Capital | $128,346 (as of Dec 28, 2002) | |||
| Total Debt (Current + Long-term) | $76,599 (as of Dec 28, 2002) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 3.2% in the quarter and 6.3% for the nine-month period. At constant currency rates, growth was 4.0% (quarter) and 7.8% (nine months), driven by volume increases in disposables and software sales.
- Profitability Surge: Operating income increased significantly (321% in the quarter) primarily due to the absence of a $10.0 million one-time expense for acquired research and development recorded in the prior year (payment to Baxter for pathogen reduction technology).
- Margin Compression: Gross margin decreased slightly (1.9% in the quarter) due to spot rate losses on forward contracts and a manufacturing provision for quality enhancements to the OrthoPAT(R) system, partially offset by cost reductions from the "CORE" program.
- Product Mix: Red Cell disposable sales grew 49.0% (quarter) due to U.S. blood shortages driving automation adoption. Bloodbank sales declined due to lower demand for ACP 215 disposables compared to the post-9/11 surge in the prior year.
Guidance, Outlook, and Risks
- Outlook: Management anticipates strong growth in OrthoPAT(R) sales to distributors in the first half of the next fiscal year following a quality enhancement program. The effective tax rate for Q4 is estimated at 36.0%.
- Contingent Liabilities:
- Baxter Agreement: Potential milestone payments up to $14.5 million for pathogen reduction technology. An initial $3.8 million payment is expected in Q4 fiscal 2003 following European regulatory approval.
- Fifth Dimension Acquisition: Potential earn-out payments up to $4.1 million based on performance milestones through fiscal 2008.
- Key Risks:
- Customer Concentration: Uncertainty regarding future sales to Alpha Therapeutic Corporation following its acquisition by Baxter International.
- Foreign Exchange: Approximately 62% of sales are international; a strengthening U.S. dollar adversely affects results. The company uses forward contracts to hedge, but volatility remains.
- Regulatory: Dependence on regulatory approvals for new technologies and changes in donor deferral regulations.
- Capital Allocation: The company repurchased $45.0 million of its own stock during the nine-month period. A new $50.0 million repurchase authorization was approved in July 2002.
Investor Verification Checklist
- Baxter Milestone Payments: Verify the timing and accounting treatment of the anticipated $3.8 million payment to Baxter in Q4 fiscal 2003.
- Alpha Therapeutic Impact: Assess the potential revenue loss from Alpha Therapeutic's acquisition by Baxter, given Alpha's exclusive purchasing contracts expiring between 2005 and 2009.
- OrthoPAT(R) Recovery: Monitor Q1 and Q2 fiscal 2004 results to confirm the anticipated rebound in OrthoPAT(R) sales following the quality enhancement program.
- Foreign Exchange Hedging: Review the effectiveness of forward contracts given the reported $4.1 million fair value liability on hedges at period end.
- Stock Repurchases: Confirm the remaining balance of the $50.0 million share repurchase authorization and its impact on future liquidity.